Home > Boards > US Listed > Biotechs > Moderna Inc. (MRNA)

MRNA Moderna currently has nine development candidates in

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
sharky Member Profile
Member Level 
Followed By 1,437
Posts 106,670
Boards Moderated 6
Alias Born 01/22/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/2/2020 7:41:31 PM
Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day Business Wire - 6/2/2020 7:30:00 AM
Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coro... Business Wire - 5/29/2020 4:52:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2020 6:08:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2020 6:05:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2020 6:02:52 PM
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-... PR Newswire (US) - 5/28/2020 8:00:00 AM
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Mod... PR Newswire (US) - 5/28/2020 1:30:00 AM
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Mod... PR Newswire (US) - 5/28/2020 1:30:00 AM
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Mod... PR Newswire (Canada) - 5/28/2020 1:30:00 AM
Moderna to Present at Upcoming Investor Conferences Business Wire - 5/27/2020 8:00:00 AM
Geopolitical Power Play Over Coronavirus Vaccine Leaves Drugmakers in the Middle Dow Jones News - 5/27/2020 7:40:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/26/2020 5:01:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/26/2020 4:38:43 PM
Moderna to Host Virtual Science Day on June 2, 2020 Business Wire - 5/26/2020 8:00:00 AM
Home Depot, Moderna, Walmart: Stocks That Defined the Week -- WSJ Dow Jones News - 5/23/2020 3:02:00 AM
Home Depot, Moderna, Walmart: Stocks That Defined the Week Dow Jones News - 5/22/2020 7:38:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:15:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:59 PM
Correction to the Drug Pricing Article Dow Jones News - 5/21/2020 7:27:00 PM
U.S. to Invest $1.2 Billion to Secure Potential Coronavirus Vaccine From AstraZeneca, Oxford University--Update Dow Jones News - 5/21/2020 2:05:00 PM
Coronavirus Revives Debate Over Drug Pricing Dow Jones News - 5/21/2020 2:04:00 PM
U.S. to Invest $1.2 Billion to Secure Potential Coronavirus Vaccine From AstraZeneca, Oxford University Dow Jones News - 5/21/2020 8:40:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 5:16:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/20/2020 5:12:26 PM
sharky Member Level  Monday, 02/10/20 07:20:48 PM
Re: None
Post # of 3592 
MRNA Moderna currently has nine development candidates in its prophylactic vaccines modality, including:

Vaccines against serious respiratory infections




Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck)




RSV vaccine for young children (mRNA-1345)




Human metapneumovirus and parainfluenza virus type 3 (hMPV/PIV3) vaccine (mRNA-1653)




Novel coronavirus (2019-nCoV) vaccine (mRNA-1273)




Influenza H7N9 (mRNA-1851)

Vaccines against serious infections transmitted from mother to baby




Cytomegalovirus (CMV) vaccine (mRNA-1647)




Zika vaccine (mRNA-1893) with the Biomedical Advanced Research and Development Authority (BARDA)

Vaccines against common viral infections with high unmet need




Epstein-Barr virus (EBV) vaccine (mRNA-1189)

To date, Moderna has demonstrated positive Phase 1 data readouts for six prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3 and CMV). Moderna’s CMV vaccine is currently in a Phase 2 dose-confirmation study. Moderna’s investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation.

Moderna has built a fully integrated manufacturing plant in Norwood, MA which enables the promise of the technology platform.


$MRNA

Surrounded by thieves, lets fight our way out!


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist